Topical Drug Treatment of Cutaneous Leishmaniasis
皮肤利什曼病的局部药物治疗
基本信息
- 批准号:9383791
- 负责人:
- 金额:$ 21.42万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-08-01 至 2019-04-30
- 项目状态:已结题
- 来源:
- 关键词:AcetatesAddressAdverse effectsAftercareAnimal ModelAnionsAreaBiodistributionBiological AssayBlood CirculationCessation of lifeChemicalsClinicalComplexCutaneousCutaneous LeishmaniasisDataDermalDevelopmentDiseaseDrug IndustryEconomicsElementsEthanolExcipientsExhibitsFDA approvedFemaleFluorescenceFormulationGelGoalsHIVHarvestHousingHumanImageImmune systemIn VitroInbred BALB C MiceIncentivesInfectionInternational Health ProblemsInvestmentsIrritantsLeishmaniaLeishmania majorLeishmaniasisLesionMalnutritionMeasuresMethodsMolecular TargetMonitorMorbidity - disease rateMusNecrosisNitratesOctanolsOintmentsOrganParasitesPermeabilityPharmaceutical PreparationsPharmacologic SubstancePharmacotherapyPhasePolyethylene GlycolsPovertyPropertyPropylene GlycolsProteinsProtozoaReportingResistanceResourcesRiskSamplingSex DiscriminationSkinSkin UlcerSliceSmall Business Innovation Research GrantStainsStructureTechnologyTestingTissue ViabilityTissuesTopical applicationToxic effectToxicologyUniversitiesVaccinationVisceralWorld Health OrganizationZincchemotherapyclinical translationclinically relevantco-infectioncohortdrug developmentdrug discoveryexpectationexperimental studyhistological stainsilliteracyin vivo Modelmortalitymouse modelnew technologynovelskin irritationskin lesionstandard measurestandard of carevector control
项目摘要
Protozoan parasites of the genus Leishmania are the causative agents of leishmaniasis, a disease
that is characterized by a spectrum of clinical manifestations ranging from ulcerative skin lesions to fatal
visceral infections. Leishmaniasis is a poverty-related disease and is associated with malnutrition,
displacement, poor housing, illiteracy, gender discrimination, weakness of the immune system and lack of
resources. Leishmaniasis is further compromised by the emergence of co-infection with human
immunodeficiency virus (HIV) in endemic areas. Globally, there are an estimated 1.5–2 million new cases of
leishmaniasis and 80,000 deaths each year, and 350 million people are at risk of infection and disease. In
the absence of vaccination, chemotherapy, together with vector control, remains one of the most important
elements in the control of leishmaniasis. However, this strategy is seriously threatened by the high toxicity
of clinical drugs and the rampant increase of resistance in the field. As leishmaniasis is a disease of
poverty, pharmaceutical companies have had limited incentive for the search of novel anti-leishmanial drugs
because there would be low economic return on their investment.
The goal of this SBIR application is to develop an affordable and effective antileishmanial ointment for
treating cutaneous leishmaniasis (CL) in both developed and developing areas of the world. Our team
recently discovered that zinc(II)-dipicolylamine (ZnDPA) complexes have strong antileishmanial activity
against Leishmania major one of the causative agents of CL. Molecular Targeting Technologies Inc. will
develop ointment formulations of ZnDPA and the team at the University of Notre Dame will test these
ointments in an in vivo model of CL that takes advantage of a genetically modified L. major strain which
stably express a red fluorescent mCherry protein. Furthermore, the proposed studies on skin toxicity and
biodistribution of ZnDPA will be significant for a successful clinical translation.
利什曼原虫属寄生虫是利什曼病的病原体。
它的特征是一系列的临床表现,从溃烂的皮肤病变到致命的
内脏感染。利什曼病是一种与贫困相关的疾病,与营养不良有关,
流离失所、住房条件差、文盲、性别歧视、免疫系统薄弱和缺乏
资源。利什曼病因出现与人类的混合感染而进一步恶化
流行地区的免疫缺陷病毒(HIV)。在全球范围内,估计有150-200万新病例
每年有8万人死于利什曼病,3.5亿人面临感染和疾病的风险。在……里面
缺乏疫苗接种、化疗以及病媒控制,仍然是最重要的因素之一。
控制利什曼病的要素。然而,这一战略受到高毒性的严重威胁。
临床药物的增加和领域中耐药性的猖獗增加。因为利什曼病是一种
贫穷,制药公司在寻找新的抗利什曼病药物方面的动机有限
因为他们的投资会有很低的经济回报。
此SBIR应用程序的目标是开发一种负担得起且有效的抗利什曼软膏
在世界发达和发展中地区治疗皮肤利什曼病(CL)。我们队
最近发现锌(II)-二吡啶甲胺(ZnDPA)络合物具有很强的抗利什曼活性
对CL的病原体之一的主要利什曼原虫。分子靶向技术公司将
开发锌DPA的软膏配方,圣母大学的团队将对这些配方进行测试
在利用转基因主要乳杆菌菌株的CL体内模型中使用软膏
稳定表达红色荧光mCherry蛋白。此外,拟议的皮肤毒性和
锌DPA的生物分布对成功的临床翻译具有重要意义。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Brian David Gray其他文献
Brian David Gray的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Brian David Gray', 18)}}的其他基金
Phosphatidylserine-blocking nanoparticles as improved anti-thrombotic with reduced bleeding risk
磷脂酰丝氨酸阻断纳米颗粒可改善抗血栓形成并降低出血风险
- 批准号:
10598788 - 财政年份:2023
- 资助金额:
$ 21.42万 - 项目类别:
Instantaneous Tumor Spray for Real-Time Surgical Guidance
用于实时手术指导的瞬时肿瘤喷雾
- 批准号:
10681383 - 财政年份:2022
- 资助金额:
$ 21.42万 - 项目类别:
Instantaneous Tumor Spray for Real-Time Surgical Guidance
用于实时手术指导的瞬时肿瘤喷雾
- 批准号:
10543617 - 财政年份:2022
- 资助金额:
$ 21.42万 - 项目类别:
Multicolor Cell Membrane Profiling For Development And Disease
发育和疾病的多色细胞膜分析
- 批准号:
8589954 - 财政年份:2013
- 资助金额:
$ 21.42万 - 项目类别:
Anionic Phospholipid-Selective PET/SPECT Agent for Infection Imaging
用于感染成像的阴离子磷脂选择性 PET/SPECT 试剂
- 批准号:
8250164 - 财政年份:2012
- 资助金额:
$ 21.42万 - 项目类别:
Dual Modality Labels for Macro and Micro Detection and Quantification of Stem Cel
用于干细胞宏观和微观检测及定量的双模态标签
- 批准号:
7909750 - 财政年份:2010
- 资助金额:
$ 21.42万 - 项目类别:
Radiohybridization Imaging of HER2 Oncogene to Detect Breast Cancer
HER2 癌基因放射杂交成像检测乳腺癌
- 批准号:
7681555 - 财政年份:2008
- 资助金额:
$ 21.42万 - 项目类别:
Radiohybridization Imaging of HER2 Oncogene to Detect Breast Cancer
HER2 癌基因放射杂交成像检测乳腺癌
- 批准号:
7536308 - 财政年份:2008
- 资助金额:
$ 21.42万 - 项目类别:
Optimizing Tracers For Multicolor Neuronal Profiling
优化多色神经元分析示踪剂
- 批准号:
7418498 - 财政年份:2004
- 资助金额:
$ 21.42万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 21.42万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 21.42万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 21.42万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 21.42万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 21.42万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 21.42万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 21.42万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 21.42万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 21.42万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 21.42万 - 项目类别:
Research Grant